Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia

Changing Trends in Antimicrobial Resistance and Serotypes of Streptococcus pneumoniae Isolates in Asian Countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study

(2012) So Hyun Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects

(2012) Keith A. Rodvold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011)

(2012) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects

(2011) J. Gordon Still et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

(2010) M. R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors

(2010) D. Bertrand et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

(2010) Thomas M. File et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates

(2010) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)

(2010) David J. Farrell et al.   JOURNAL OF INFECTION

Emerging Macrolide Resistance in Mycoplasma pneumoniae in Children

(2010) Xiao Li et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101

(2009) K. B. Waites et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages

(2009) S. Lemaire et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

(2008) Margaret R Hammerschlag et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004)

(2008) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS